At a Glance
- Company: Johnson & Johnson (NYSE: JNJ)
- Location: Montgomery County (Lower Gwynedd), Pennsylvania
- Deal value: Over $1 billion
- Focus area: Cell therapies for cancer, immune, neurological diseases
- Next steps: Construction starts later 2026; operational by end-2031
What happened?
Johnson & Johnson announced a more than $1 billion investment in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, on its Janssen Biotech campus. The advanced site will expand US production capacity for transformational cell therapies. This forms part of J&J’s $55 billion US investment through early 2029.
Why does it matter?
Cell therapies demand scalable manufacturing for cancer, autoimmune and neurological treatments; this facility adopts cutting-edge tech to meet growing pipeline needs, onshore production amid supply chain pressures. It boosts Pennsylvania’s $10B annual J&J economic impact, creating 500 skilled biomanufacturing jobs and over 4,000 construction roles.
Who’s behind it?
J&J, led by CEO Joaquin Duato, operates ten Pennsylvania facilities (>2M sq ft). Pennsylvania Governor Josh Shapiro secured $41.5M state funding; supported by Senator Dave McCormick and Rep. Madeleine Dean.
How was it achieved?
The facility leverages innovative cell therapy processes on the existing Spring House campus near Ambler, focusing on advanced biomanufacturing for J&J’s portfolio. It aligns with workforce training for future tech.
What’s next?
Construction begins later 2026; full operations by end-2031. Supports majority US production of advanced medicines.
What are people saying?
“By uniting scientific excellence with state-of-the-art manufacturing… we are delivering for patients,” said J&J CEO Joaquin Duato. Gov. Shapiro: “Pennsylvania… power for innovation manufacturing in life sciences.”